Diabetic Somatic Neuropathy

Kamenov, Zdravko; Traykov, Latchezar

doi:10.1007/978-1-4614-5441-0_14

Cited by 7 publications

(5 citation statements)

References 104 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are several underlying mechanisms suggested to be linked to the development and progression of DPN caused by dyslipidemias [ 11 ]. A convergent point for such mechanisms is thought to be OS, which is suggested to be responsible for the pathophysiologic changes observed in T2DM subjects that leads to axonal degeneration and segmental demyelination, thereby promoting DPN [ 2 – 4 ]. LPO has been frequently associated with OS in human diseases and is commonly used as biomarker of OS [ 27 , 28 ].…”

Section: Discussionmentioning

confidence: 99%

“…Nerve damage in patients with diabetes is known as diabetic neuropathy and is considered as the most prevalent microvascular complication—up to 60%—in Type 2 Diabetes Mellitus (T2DM) subjects [ 1 ]. Diabetic polyneuropathy (DPN) comprises approximately 70% of all cases [ 2 ]. DPN diagnosis is established by means of validated scores based on clinical features and abnormal nerve conduction studies (NCS) [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of Ezetimibe/Simvastatin and Rosuvastatin on Oxidative Stress in Diabetic Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Villegas-Rivera¹,

Román-Pintos

Cardona-Muñoz

et al. 2015

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Objective. To evaluate the effects of ezetimibe/simvastatin (EZE/SIMV) and rosuvastatin (ROSUV) on oxidative stress (OS) markers in patients with diabetic polyneuropathy (DPN). Methods. We performed a randomized, double-blind, placebo-controlled phase III clinical trial in adult patients with Type 2 Diabetes Mellitus (T2DM) and DPN, as evaluated by composite scores and nerve conduction studies (NCS). Seventy-four subjects with T2DM were allocated 1 : 1 : 1 to placebo, EZE/SIMV 10/20 mg, or ROSUV 20 mg for 16 weeks. All patients were assessed before and after treatment: primary outcomes were lipid peroxidation (LPO), and nitric oxide (NO) surrogate levels in plasma; secondary outcomes included NCS, neuropathic symptom scores, and metabolic parameters. Data were expressed as mean ± SD or SEM, frequencies, and percentages; we used nonparametric analysis. Results. LPO levels were reduced in both statin arms after 16 weeks of treatment (p < 0.05 versus baseline), without changes in the placebo group. NO levels were not significantly affected by statin treatment, although a trend towards significance concerning increased NO levels was noted in both statin arms. No significant changes were observed for the NCS or composite scores. Discussion. EZE/SIMV and ROSUV are superior to placebo in reducing LPO in subjects with T2DM suffering from polyneuropathy. This trial is registered with NCT02129231.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Effects of Ezetimibe/Simvastatin and Rosuvastatin on Oxidative Stress in Diabetic Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Villegas-Rivera¹,

Román-Pintos

Cardona-Muñoz

et al. 2015

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

show abstract

“…The sensation of pain is substantially decreased as a consequence of chronic sensory neuropathy. Consequently, the risk for trauma is significantly higher [ 18 , 19 , 20 , 21 ]. Due to the missing pain symptomatology, serious ulcerations are underestimated by both patient and doctor [ 22 , 23 ].…”

Section: Diabetic Neuropathymentioning

confidence: 99%

Neuropathy and Diabetic Foot Syndrome

Volmer-Thole

Lobmann

2016

IJMS

304

205

View full text Add to dashboard Cite

Diabetic foot ulceration is a serious complication of diabetes mellitus worldwide and the most common cause of hospitalization in diabetic patients. The etiology of diabetic foot ulcerations is complex due to their multifactorial nature; in the pathophysiology of diabetic foot ulceration polyneuropathy is important. Proper adherence to standard treatment strategies and interdisciplinary cooperation can reduce the still high rates of major amputations.

show abstract

“…The sensation of pain in the foot is substantially declined as a consequence of chronic sensory neuropathy. As a result, the risk of foot trauma is significantly higher (26)(27)(28)(29). Foot injuries and ulcers are neglected by patients and doctors due to the lack of pain symptoms (30,31).…”

Section: Discussionmentioning

confidence: 99%

Nomogram Prediction for the Risk of Diabetic Foot in Patients With Type 2 Diabetes Mellitus

Wang

Xue

et al. 2022

Front. Endocrinol.

View full text Add to dashboard Cite

AimsTo develop and validate a nomogram prediction model for the risk of diabetic foot in patients with type 2 diabetes mellitus (T2DM) and evaluate its clinical application value.MethodsWe retrospectively collected clinical data from 1,950 patients with T2DM from the Second Affiliated Hospital of Xi’an Jiaotong University between January 2012 and June 2021. The patients were divided into training cohort and validation cohort according to the random number table method at a ratio of 7:3. The independent risk factors for diabetic foot among patients with T2DM were identified by multivariate logistic regression analysis. Then, a nomogram prediction model was developed using the independent risk factors. The model performances were evaluated by the area under the receiver operating characteristic curve (AUC), calibration plot, Hosmer–Lemeshow test, and the decision curve analysis (DCA).ResultsMultivariate logistic regression analysis indicated that age, hemoglobin A1c (HbA1c), low-density lipoprotein (LDL), total cholesterol (TC), smoke, and drink were independent risk factors for diabetic foot among patients with T2DM (P < 0.05). The AUCs of training cohort and validation cohort were 0.806 (95% CI: 0.775∼0.837) and 0.857 (95% CI: 0.814∼0.899), respectively, suggesting good discrimination of the model. Calibration curves of training cohort and validation cohort showed a favorable consistency between the predicted probability and the actual probability. In addition, the P values of Hosmer–Lemeshow test for training cohort and validation cohort were 0.826 and 0.480, respectively, suggesting a high calibration of the model. When the threshold probability was set as 11.6% in the DCA curve, the clinical net benefits of training cohort and validation cohort were 58% and 65%, respectively, indicating good clinical usefulness of the model.ConclusionWe developed and validated a user-friendly nomogram prediction model for the risk of diabetic foot in patients with T2DM. Nomograms may help clinicians early screen and identify patients at high risk of diabetic foot.

show abstract

Diabetic Somatic Neuropathy

Cited by 7 publications

References 104 publications

Effects of Ezetimibe/Simvastatin and Rosuvastatin on Oxidative Stress in Diabetic Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Effects of Ezetimibe/Simvastatin and Rosuvastatin on Oxidative Stress in Diabetic Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Neuropathy and Diabetic Foot Syndrome

Nomogram Prediction for the Risk of Diabetic Foot in Patients With Type 2 Diabetes Mellitus

Contact Info

Product

Resources

About